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 2
ABSTRACT 24 
Canine influenza is a respiratory disease of dogs caused by canine influenza virus 25 
(CIV). CIV subtypes responsible for influenza in dogs include H3N8, which originated 26 
from the transfer of H3N8 equine influenza virus to dogs; and the H3N2 CIV, which is an 27 
avian-origin virus that adapted to infect dogs. Influenza infections are most effectively 28 
prevented through vaccination to reduce transmission and future infection. Currently, 29 
only inactivated influenza vaccines (IIVs) are available for the prevention of CIV in dogs. 30 
However, the efficacy of IIVs is suboptimal and novel approaches are necessary for the 31 
prevention of disease caused by this canine respiratory pathogen. Using reverse 32 
genetics techniques, we have developed a live-attenuated CIV vaccine (LACIV) for the 33 
prevention of H3N8 CIV. The H3N8 LACIV replicates efficiently in canine cells at 33oC 34 
but is impaired at 37-39oC temperatures, and was attenuated when compared to wild-35 
type H3N8 CIV, in vivo and ex vivo. The LACIV was able to induce protection against 36 
H3N8 CIV challenge with a single intranasal inoculation in mice. Immunogenicity and 37 
protection efficacy were better than that observed with a commercial CIV H3N8 IIV, but 38 
provided limited cross-reactive immunity and heterologous protection against H3N2 CIV. 39 
These results demonstrate the feasibility of implementing a LAIV approach for the 40 
prevention and control of H3N8 CIV in dogs and suggest the need for a new LAIV for 41 
the control of H3N2 CIV. 42 
 43 
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 45 
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IMPORTANCE 47 
Two influenza A virus subtypes has been reported in dogs in the last 16 years - the 48 
canine influenza virus (CIV) H3N8 and H3N2 of equine and avian origin, respectively. 49 
To date, only inactivated influenza vaccines (IIVs) are available to prevent CIV 50 
infections. Here we report the generation of a recombinant, temperature sensitive H3N8 51 
CIV as a live-attenuated influenza vaccine (LAIV), which was attenuated in mice and 52 
dog tracheal, explants when compared to CIV H3N8 wild-type. A single dose of H3N8 53 
LACIV showed immunogenicity and protection against a homologous challenge that 54 
was better than that conferred with an H3N8 IIV, demonstrating the feasibility of 55 
implementing a LAIV approach for the improved control of H3N8 CIV infections in dogs. 56 
 57 
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INTRODUCTION 70 
Influenza A viruses (IAVs) are enveloped viruses that belong to the 71 
Orthomyxoviridae family, and contain a genome that comprises eight single-stranded 72 
negative-sense RNA segments that encode for 10–14 proteins (1). The hemagglutinin 73 
(HA) and the neuraminidase (NA) glycoproteins are the major antigenic determinants of 74 
IAV and are essential for receptor binding and fusion, and virion release, respectively 75 
(2). IAV HA and NA glycoproteins within infected organisms and populations are driven 76 
to evolve antigenic variants via immunological pressure, and in humans and some other 77 
hosts positive selection of viruses occurs gradually in a process known as antigenic drift 78 
(3). The antigenic diversity of glycoproteins is used to further classify IAVs, of which 79 
there are 18 HA and 11 NA subtypes (4, 5). In addition, antigenically distinct isolates 80 
can also exist within the same subtype, referred to as drifted variants. IAVs exist mainly 81 
in the wild aquatic fowl reservoir (6-9) and only a small number of mammalian hosts are 82 
currently recognized as sustaining transmission of IAVs.  83 
Canine influenza is a contagious respiratory disease of dogs caused by two IAVs: 84 
the H3N8 equine-origin influenza virus that transferred to dogs in the United States (US) 85 
around 1999 (10); and the avian virus-like H3N2 that transferred to dogs in Asia around 86 
2005 (11). In 2015 an outbreak of H3N2 canine influenza virus (CIV) occurred in the US 87 
that was due to a virus similar to those detected in dogs in Asia (12). The H3N2 CIV has 88 
also been isolated from cats in a shelter in South Korea (13, 14). These CIVs represent 89 
new threats to canine health in the US and worldwide, as the virus may be spread 90 
through the racing track circuit, as was the case of the H3N8 strain (10, 15), while both 91 
viruses are spread widely within and among animal shelters and kennels (10, 16, 17). 92 
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 5
CIVs are still relatively new viruses and because of the low levels of infection and 93 
immunity among the broader population most dogs are susceptible to infection. Most 94 
dogs infected by CIVs show only a mild respiratory illness, but severe outcomes are 95 
also observed (18).  96 
The recent emergence of CIVs (H3N8 and H3N2 CIVs) has increased the host 97 
range of IAVs. The continuous circulation of CIVs in dog populations creates  98 
opportunities for exposure of humans and other animals. As dogs are susceptible to 99 
mammalian (equine-origin H3N8 CIV) and avian (avian-origin H3N2 CIV) IAVs, they 100 
may have the potential to act as “mixing vessel” hosts for new IAV strains with potential 101 
for human infection. Reassortments between H3N2 CIVs and human pandemic H1N1 102 
IAV have been reported (19, 20), and the introduction of novel, antigenically distinct 103 
glycoproteins (HA and NA) into the backbone of human IAVs have been associated with 104 
human pandemics (21).  105 
Vaccination is accepted as an effective strategy for the prevention of influenza 106 
infections (22, 23). To date, three types of influenza virus vaccines have been approved 107 
by the US Food and Drug Administration (FDA) for human use: recombinant viral HAs, 108 
inactivated influenza vaccines (IIVs), and live attenuated influenza vaccines (LAIVs) 109 
(24-26, 22, 27). In dogs, only IIV against both H3N8 and H3N2 CIVs are commercially 110 
available. However, we have recently reported the generation of recombinant H3N8 111 
CIVs containing truncated or a deleted non-structural 1 (NS1) protein as potential LAIVs 112 
candidates for the treatment of H3N8 CIV infections (28). 113 
IIVs are administered intramuscularly and elicit humoral immunity by inducing the 114 
production of neutralizing antibodies that target epitopes on HA (29, 26). On the other 115 
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hand, LAIV more closely mimic the natural route of viral infection and elicit both cellular 116 
and humoral immune responses (24), providing better immunogenicity and protection 117 
(30, 31, 22).  118 
In mammals IAV is a respiratory pathogen that replicates in the cooler (33oC) upper 119 
respiratory tract, in addition to replicating in the warmer (37oC) conditions of the lower 120 
respiratory tract (32). This temperature difference has allowed for the development of 121 
cold-adapted (ca), temperature-sensitive (ts), attenuated (att) viruses that replicate in 122 
the upper respiratory tract but do not damage the lower respiratory tract due to the 123 
elevated temperatures restricting replication (33). For human viruses these ca, ts, att 124 
properties have been mapped to five amino acid residues located in three viral proteins 125 
of A/Ann Arbor/6/60 H2N2 (A/AA/6/60): the polymerase basic 2 (PB2) N265S, the 126 
polymerase basic 1 (PB1) K391E, D581G, and A661T and the nucleoprotein (NP) 127 
D34G (34, 35). The mechanisms of attenuation are not fully understood but most likely 128 
involve multiple steps in the replication cycle of the virus (33). Importantly, when the ts 129 
signature of A/AA/6/60 was introduced into influenza A/Puerto Rico/8/34 H1N1 (PR8) or 130 
A/California/04/09 H1N1 (pH1N1) viruses, a similar ts phenotype was observed in tissue 131 
culture cells and in the mouse model of infection (36-38).  132 
In order to develop a LAIV for the treatment of CIV H3N8 infections, we introduced 133 
the ts, ca, att mutations identified in the A/AA/6/60 LAIV into CIV H3N8 (referred to 134 
henceforth as LACIV H3N8) using reverse genetics (39). LACIV H3N8 replicated 135 
efficiently in vitro at 33ºC but not 37ºC or 39ºC. Compared to CIV H3N8 wild-type (WT), 136 
LACIV H3N8 was attenuated ex vivo and in vivo but was able to induce protective 137 
immunity in mice against H3N8 WT upon a single intranasal dose, demonstrating its 138 
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feasibility as a safe, immunogenic and protective LAIV candidate. 139 
 140 
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 8
MATERIALS AND METHODS  162 
Cells and viruses  163 
Human embryonic kidney 293T cells (293T; ATCC CRL-11268) and Madin-Darby 164 
canine kidney cells (MDCK; ATCC CCL-34) were grown at 37ºC with 5% CO2, in 165 
Dulbecco’s modified Eagle’s medium (DMEM; Mediatech, Inc.) supplemented with 10% 166 
fetal bovine serum (FBS), and 1% PSG (penicillin, 100 units/ml; streptomycin 100 µg/ml; 167 
L-glutamine, 2 mM) (40).  168 
Recombinant wild-type (WT) and live-attenuated (LACIV) H3N8 CIVs were 169 
generated using A/canine/NY/dog23/2009 H3N8 plasmid-based reverse genetics 170 
techniques (41) and grown in MDCK cells at 33ºC. Influenza A/Ca/IL/41915/2015 H3N2 171 
was also grown in MDCK cells at 33ºC. For infections, virus stocks were diluted in 172 
phosphate buffered saline (PBS), 0.3% bovine albumin (BA) and 1% PS (PBS/BA/PS). 173 
After viral infections, cells were maintained in DMEM with 0.3% BA, 1% PSG, and 1 174 
μg/ml TPCK-treated trypsin (Sigma) (39).  175 
Plasmids 176 
To generate H3N8 LACIV, the PB2 and PB1 genes were subcloned in a pUC19 177 
plasmid (New England Biolabs) and then ts mutations (PB2 N265S; and PB1 K391E, 178 
D581G, and A661T) were introduced by site-directed mutagenesis. The presence of 179 
introduced mutations was confirmed by sequencing. Mutated PB2 and PB1 viral 180 
segments were subcloned from pUC19 into the ambisense pDZ plasmid for virus rescue. 181 
To test the ability of WT and LACIV H3N8 polymerases to replicate and transcribe at 182 
different temperatures (33ºC, 37ºC and 39ºC) using a minigenome assay, we 183 
engineered a pPolI plasmid containing the canine RNA polymerase I (Pol-I) promoter 184 
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and the mouse Pol-I terminator separated by SapI endonuclease restriction sites 185 
(cpPol-I). The canine Pol-I promoter was obtained by PCR from MDCK cells (42). 186 
Then, the Gaussia luciferase (Gluc) reporter gene containing the 3’ and the 5’ non-187 
coding regions of the viral NP (v)RNA was cloned into the cpPol-I plasmid to generate 188 
the cpPol-I Gluc reporter plasmid. All plasmids were confirmed by sequencing (ACGT, 189 
Inc). Primers for the generation of the different plasmids are available upon request. 190 
Minigenome assays 191 
MDCK cells (12-well plate format, 5x105 cells/well, triplicates) were co-transfected in 192 
suspension using Lipofectamine 2000 with 250 ng of each of the H3N8 WT or LACIV 193 
ambisense pDZ PB2, PB1, PA and NP plasmids, together with 500 ng of the cpPol-I 194 
Gluc plasmid. A mammalian expression pCAGGS plasmid 195 
encoding Cypridina luciferase (Cluc, 100 ng) was also included to normalize 196 
transfection efficiencies (43). Cells transfected in the absence of the pDZ NP plasmid 197 
were used as negative control. At 24 hours (h) post-transfection, Gluc and Cluc 198 
expression levels were determined using a Luciferase Assay kit (New England BioLabs) 199 
and quantified with a Lumicount luminometer (Packard). Fold induction over the level of 200 
induction for the negative control (absence of NP) was determined. The mean values 201 
and standard deviations (SDs) were calculated and statistical analysis was performed 202 
using a two-tailed Student t test using Microsoft Excel software. 203 
Virus rescue 204 
Virus rescues were performed as previously described (44, 40). Briefly, co-cultures 205 
(1:1) of 293T/MDCK cells (6-well plate format, 106 cells/well, triplicates) were co-206 
transfected in suspension, using Lipofectamine 2000 (Invitrogen), with 1 µg of the eight-207 
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 10
ambisense H3N8 WT CIV (pDZ-PB2, -PB1, -PA, -HA, -NP, -NA, -M and –NS) plasmids. 208 
To rescue the H3N8 LACIV, WT PB2 and PB1 pDZ plasmids were substituted by those 209 
containing PB2 and PB1 H3N8 LACIV. At 12 h post-transfection, transfection medium 210 
was replaced with post-infection (p.i.) medium containing DMEM supplemented with 211 
0.3% BSA, 1% PSG, and 0.5 µg/ml TPCK-treated trypsin (Sigma). Tissue culture 212 
supernatants (TCS) were collected 3 days post-transfection, clarified, and used to infect 213 
fresh monolayers of MDCK cells (6-well plate format, 106 cells/well, triplicates). At 3 214 
days p.i., recombinant viruses were plaque purified and scaled up using MDCK cells at 215 
33ºC (40). Virus stocks were titrated by standard plaque assay (plaque forming units, 216 
PFU/ml) in MDCK cells at 33ºC (40).  217 
Virus growth kinetics  218 
Multicycle growth analyses were performed by infecting confluent monolayers of 219 
MDCK cells (12-well plate format, 5x105 cells/well, triplicates) at a multiplicity of infection 220 
(MOI) of 0.001. Viral titers in TCS collected at various times p.i. were determined by 221 
immunofocus assay (fluorescent forming units, FFU/ml) in MDCK cells as previously 222 
described (40). Briefly, confluent MDCK cells (96-well plate format, 5 x104 cells/well, 223 
triplicates) were infected with 10-fold serial dilutions of H3N8 WT or LACIV. At 12 h p.i., 224 
cells were fixed and permeabilized (4% formaldehyde, 0.5% Triton X-100 in PBS) for 15 225 
min at room temperature. After washing with PBS, cells were incubated in blocking 226 
solution (2.5% BSA in PBS) for 1 h at room temperature and then incubated with 1µg/ml 227 
of an anti-NP monoclonal antibody (HB-65, ATTC) for 1 h at 37ºC. After washing with 228 
PBS, cells were incubated with FITC-conjugated secondary anti-mouse antibody (Dako) 229 
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 11
for 1 h at 37°C. The mean values and SDs were calculated using Microsoft Excel 230 
software.  231 
Animal experiments 232 
Adult (5- to 7-week-old) female WT C57BL/6 mice were purchased from the National 233 
Cancer Institute (NCI) and maintained in the animal care facility at the University of 234 
Rochester under specific pathogen-free conditions. Animal experiments were approved 235 
by the University Committee of Animal Resources and complied with the 236 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 237 
National Research Council (45). Mice were anesthetized intraperitoneally (i.p.) with 238 
2,2,2-tribromoethanol (Avertin; 240 mg/kg of body weight) and then inoculated 239 
intranasally (i.n.) with 30 µl of the indicated amounts of H3N8 WT or LACIV or H3N2 WT. 240 
Alternatively, 100 µl of a commercially available inactivated H3N8 CIV vaccine (Nobivac, 241 
Merck Animal Health) or inactivated H3N2 CIV vaccine (Zoetis) were inoculated 242 
intramuscularly (i.m). Virus replication was determined by measuring viral titers in the 243 
lungs of infected mice at the indicated days p.i. To that end, three mice in each group 244 
were euthanized by administration of a lethal dose of Avertin and exsanguination, and 245 
lungs were collected and homogenized. Virus titers were determined by immunofocus 246 
assay (FFU/ml) as indicated above. Mice sera were collected by submandibular 247 
bleeding 24 h prior to viral challenges and evaluated for the presence of influenza virus 248 
antibodies by enzyme-linked immunosorbent assays (ELISA) and neutralizing 249 
antibodies by hemagglutination inhibition (HAI) assays. 250 
Evaluation of T cells response in lung and spleen 251 
Mice (N=4) were immunized as describe above, with 103 PFU of H3N8 WT or LACIV, 252 
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 12
mock vaccinated with PBS, or vaccinated with 100 µl of Nobivac (IIV).  253 
Cellular Preparations: Ten days p.i.,  lungs and spleens were perfused with PBS, 254 
removed, and separated into right and left lobes. Lung tissue was dissociated in C 255 
tubes by the GentleMACS (Miltenyi Biotek) using the Lung01 program. Samples 256 
were incubated in 5 mL [2µg/mL] Collagenase II in RPMI +8% FBS at 37°C for 30 257 
minutes, with gentle agitation every 10 minutes. After digestion, samples were 258 
further dissociated using the Heart01 program. Cell suspensions were filtered 259 
through 70 µm filters prior to 75:40 Percoll (GE Healthcare) discontinuous gradient 260 
separation. The top layer, containing fat and other debris, was removed by 261 
aspiration. The cell layer was harvested and washed, prior to counting and staining. 262 
Single-cell suspensions were prepared from collected spleens by disruption in RPMI 263 
+8% FBS. Counting was achieved through Trypan blue exclusion on a hemocytometer. 264 
Flow cytometry: Single cell suspensions were stained in PBS containing 1% 265 
FBS, purified CD16/32 (clone 2.4G2), NP and PA tetramers (46), and the following 266 
antibodies: TCRβ-PerCPCy5.5, CD8α-FITC, CD4-BV421, CD44-APCCy7, and CD62L-267 
PECy7. Cells were subsequently stained for viability using Live Dead Aqua (Invitrogen). 268 
All antibodies were obtained from eBioscience, BD Biosciences, or Biolegend. PA and 269 
NP tetramers were obtained from the NIH tetramer core facility (Atlanta, GA). Cells 270 
were analyzed by an LSRII (BD Biosciences) in the University of Rochester Flow 271 
Cytometry core facility and analyzed using FlowJo software (Tree Star). 272 
ELISAs 273 
ELISAs were performed as previously described (40) by coating 96-well plates at 274 
4°C for 16 h with lysates from mock, H3N8 or H3N2 WT CIV-infected MDCK cells, or 275 
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 13
with H3N2 CIV HA (250 ng per well; catalog number for IRR: FR-1478) or NA (250 ng 276 
per well; catalog number for IRR: FR-1479). After blocking with 1% BSA for 1 h at room 277 
temperature, plates were incubated with 2-fold serial dilutions (starting dilution of 1:50) 278 
of mice sera for 1 h at 37°C. After incubation, plates were washed with H2O, and 279 
incubated with a HRP-conjugated goat anti-mouse IgG (1:2,000; Southern Biotech) for 1 280 
h at 37°C. Reactions were then developed with tetramethylbenzidine (TMB) substrate 281 
(BioLegend) for 10 min at room temperature, quenched with 2N H2SO4, and read at 450 282 
nm (Vmax kinetic microplate reader; Molecular Devices). 283 
HAI assays 284 
To evaluate the presence of H3N8 CIV neutralizing antibodies, mice sera were 285 
treated with receptor-destroying enzyme (RDE; Denka Seiken) and heat inactivated for 286 
30 min at 56°C. Sera were then serially 2-fold diluted (starting dilution of 1:50) in 96-well 287 
V-bottom plates and mixed 1:1 with 4 hemagglutinating units (HAU) of WT H3N8 CIV for 288 
30 min at room temperature. The HAI titers were determined by adding 0.5% turkey red 289 
blood cells (RBCs) to the virus-antibody mixtures for 30 min on ice, as previously 290 
described (40). The GMT and SDs from individual mice (N= 6) were calculated from the 291 
last well where hemagglutination was inhibited. 292 
Canine tracheal explants preparation and virus titrations 293 
Three dog tracheas were harvested from healthy Beagles (Charles River 294 
Laboratories) that had been used as negative controls in unrelated studies. Briefly, 295 
tracheas were collected aseptically immediately upon euthanasia and transported in 296 
pre-warmed medium as previously described (18). Tracheas were washed 5 times for a 297 
total period of 4h and maintained at 33°C, 5% CO2, and 95% humidity between washes. 298 
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The connective tissue was removed and the trachea was then open lengthwise. Each 299 
tracheal ring was divided in four 0.25 cm2 explants and transferred with the epithelium 300 
facing upwards onto an agarose plug covered by a sterile filter. The explants were kept 301 
for a total of 6 days at 33°C, 5% CO2, and 95% humidity. 302 
Tracheal explants were infected after a period of 24 h post-preparation (designed as 303 
day zero) with 200 PFU of WT or LACIV H3N8, or mock infected with culture medium. 304 
Inoculated explants were sampled for virus quantification, bead clearance assays, and 305 
histology at days 0, 1, 3 and 5 p.i. Viral replication was evaluated by plaque assays on 306 
MDCK cells.  307 
Estimation of bead clearance time 308 
The ciliary function of tracheal explants was evaluated as previously described (18), 309 
by placing five microliters of polystyrene microsphere beads (Polysciences, 310 
Northampton, UK) on the explants apical surface and measuring the time to displace 311 
the beads. 312 
Histological analysis and immunohistochemistry 313 
After collection, the explants were fixed in 10% buffered formalin for a minimum of 314 
48 h, before paraffin embedding and sectioning. Subsequently, 4 μm sections of paraffin 315 
embedded tissue were either stained with haematoxylin and eosin (H&E) for 316 
histopathological evaluation or immunostained for the viral NP using standard 317 
procedures as previously described (18). For NP immunostaining, the Dako supervision 318 
system was used following the manufacturer’s instructions, along with a monoclonal 319 
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mouse anti-NP (clone HB65; dilution 1:500). Slides were counterstained with Mayer’s 320 
hematoxylin. Histological images were captured with cellD software (Olympus). 321 
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RESULTS 343 
Generation and characterization of H3N8 LACIV  344 
We introduced four ts mutations identified in previous studies into the PB2 and PB1 345 
genes of H3N8 CIV (34, 47) (Fig. 1). No mutation was introduced into the viral NP since 346 
H3N8 CIV NP already contains a G at position 34.  347 
To determine whether the mutations introduced into the PB2 and PB1 genes confer 348 
a ts phenotype to the H3N8 CIV polymerase, we performed a minigenome assay. Both, 349 
WT and LACIV H3N8 resulted in similar Gluc expression levels at 33ºC (Fig. 1B), but 350 
Gluc expression was reduced at higher temperatures (37ºC and 39ºC) in cells 351 
transfected with the H3N8 LACIV plasmids. This shows that those mutations resulted in 352 
a ts phenotype when introduced in the H3N8 CIV, as previously described for A/AA/6/60 353 
H2N2 and other influenza viruses (36-38). 354 
We next generated an H3N8 LACIV using plasmid-based reverse genetic 355 
approaches (40, 48) and evaluated the viral replication kinetics in MDCK cells infected 356 
at low (0.001) MOI, and compared to the WT H3N8 CIV (Fig. 2). At 33ºC, both WT and 357 
LACIV H3N8 grew with the same kinetics and reached similar high titers (107 FFU/ml) at 358 
48-72 h p.i. (Fig. 2A). At higher temperatures (37ºC and 39ºC) the WT H3N8 CIV 359 
replicated at similar levels as those observed at 33ºC while H3N8 LACIV titers were 360 
reduced ~2-3-logs at 37ºC (Fig. 2B) or was not detected at 39ºC (Fig. 2C). These 361 
results demonstrate that mutations introduced in PB2 and PB1 conferred a ts phenotype 362 
to H3N8 CIV. 363 
LACIV H3N8 is attenuated in vivo in mice 364 
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As the H3N8 LACIV presented defects in replication at higher (37ºC and 39ºC) 365 
temperatures, we next investigated whether H3N8 LACIV was also attenuated in mice. No 366 
signs of infection were detected after infection with WT H3N8 CIV. Therefore, CIV titers in the 367 
lungs of infected (105 PFU) mice were determined on days 2 (N=3) and 4 (N=3) p.i. and used 368 
as a measure of viral attenuation (Fig. 3). Notably, virus titers in the lungs were only detected 369 
in mice inoculated with WT H3N8 CIV and no virus was detected in mice infected with the 370 
H3N8 LACIV. These results indicate that H3N8 LACIV is also attenuated in vivo.  371 
Intranasal vaccination with H3N8 LACIV induces protective immunity against 372 
WT H3N8 CIV challenge 373 
To evaluate the immunity generated by the H3N8 LACIV, mice (N=6) were 374 
vaccinated (i.n.) with 103 PFU of H3N8 WT or LACIV, mock vaccinated with PBS, or 375 
vaccinated (i.m.) with 100 µl of Nobivac, a commercial IIV against H3N8 CIV (Fig. 4). 376 
Humoral immune responses were evaluated in mice sera collected 2 weeks later (Fig. 377 
4A). Total H3N8 CIV antibody responses were characterized by ELISA using cell 378 
lysates from mock- or H3N8 CIV-infected MDCK cells (48). Mice vaccinated with the 379 
H3N8 LACIV elicited high serum IgG titers against parental H3N8 CIV, while antibody 380 
titers of mice vaccinated with Nobivac were lower than those in the H3N8 LACIV or WT 381 
vaccinated mice (Fig. 4A). Additionally, HAI assays were performed to examine the 382 
presence of anti-HA neutralizing antibodies on sera from vaccinated mice (Fig. 4B), 383 
showing that HAI titers against CIV H3N8 were higher in mice vaccinated with the H3N8 384 
LACIV than those observed in mice vaccinated with the H3N8 IIV.  385 
To further examine the immunogenicity of LACIV, we evaluated if the virus can 386 
induce a localized CD8 T cell response (Fig. 5). To this end, mice (N=4) were 387 
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immunized as described above and ten days p.i., lungs and spleen samples were 388 
collected and single-cell preparations made for flow cytometric analysis (49). Live, CD8 389 
T cells were further gated for a H3N8 CIV-specific population (49, 46). Results showed 390 
that vaccination with H3N8 LACIV induced elevated levels of NP and PA-specific lung 391 
CD8 T cells, similar to those induced by WT virus in both lungs (Fig. 5A) and spleen 392 
(Fig. 5B). Importantly, animals vaccinated with Nobivac did not show a T cell response 393 
either in the lung (Fig. 5A) or the spleen (Fig. 5B), highlighting important differences in 394 
induced immunity between  H3N8 LACIV and the H3N8 IIV.  395 
We next evaluated the ability of H3N8 LACIV to induce protective immunity. Mice 396 
(N=6) were vaccinated i.n. with 103 PFU of H3N8 WT or LACIV, i.m. with 100 µl of the 397 
IIV Nobivac, or mock vaccinated with PBS. Two weeks later mice were challenged with 398 
105 PFU of WT H3N8 CIV and viral titers in the lungs of infected mice (N=3/group) were 399 
determined 2 and 4 days after challenge (Fig. 6). Mock-vaccinated mice showed high 400 
viral titers in the lungs at days 2 and 4 p.i., while mice immunized with H3N8 WT CIV 401 
and with LACIV showed no detectable virus in the lungs at those times (Fig. 6). Mice 402 
vaccinated with the H3N8 IIV showed high viral titers at day 2, but no detectable virus at 403 
day 4 p.i. (Fig. 6).  404 
H3N8 LACIV is attenuated in canine tracheal explants as compared to H3N8 405 
WT CIV  406 
To compare LACIV and WT H3N8 CIV pathogenicity and replication efficiency at the 407 
site of infection within dogs (Fig. 7), we inoculated dog tracheal explants with each virus 408 
and compared histological lesions (Fig. 7A), viral NP expression (Fig. 7B), changes in 409 
ciliary function (Fig. 7C) and viral replication (Fig. 7D) at different times (days 1, 3 and 410 
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5) p.i. The H3N8 WT CIV induced major histological changes in dog tracheal explants, 411 
with thinning and desquamation of the epithelium, loss of cilia (Fig 5A), and significant 412 
reduction of ciliary function (Fig. 7C) between days 1 and 5 p.i. Histological damages 413 
induced by H3N8 LACIV were delayed and reduced compared to WT H3N8 CIV, as the 414 
epithelium maintained its normal thickness until day 3 p.i. (Fig. 7A) and the ciliary 415 
function (Fig. 7C) was only significantly reduced from day 3 p.i. Viral kinetics (Fig. 7D) 416 
and NP expression (Fig. 7B) were comparable between the two viruses, although only 417 
WT H3N8 CIV was detectable at day 1 p.i. (Fig. 7D). Overall, these results indicate that 418 
H3N8 LACIV pathogenicity is attenuated in canine tracheal explants compared to its WT 419 
counterpart. 420 
H3N8 LACIV provides limited protection against heterologous H3N2 CIV 421 
challenge  422 
We next evaluated if H3N8 LACIV could induce protective immunity against a 423 
heterologous H3N2 CIV challenge (Fig. 8). Mice  (N=6) were vaccinated (i.n.) with 103 424 
PFU of WT or LACIV H3N8, mock vaccinated with PBS, or vaccinated (i.m.) with 100 µl 425 
of the H3N8 IIV Nobivac or a commercial H3N2 IIV (Zoetis). Antibodies against H3N2 426 
CIV were evaluated by ELISA using cell lysates from mock- or H3N2 CIV-infected 427 
MDCK cells as antigens (Fig. 8A). In addition, antibodies against the HA (Fig. 8B) or 428 
NA (Fig. 8C) proteins of H3N2 CIV were also evaluated. When the cell lysate was used 429 
as antigen, antibodies against H3N2 CIV were detected in sera of mice vaccinated with 430 
WT H3N8 CIV and, to a lower extent, in mice vaccinated with H3N8 LACIV, although 431 
the levels were lower than those against H3N8 CIV (Fig. 8A). Similarly, using the 432 
recombinant proteins (HA or NA) as antigens to perform the ELISA, only antibodies 433 
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against H3N2 CIV HA were detected in samples of animals immunized with WT H3N8 434 
CIV (Fig. 8B). However no antibodies were detected against the NA protein (Fig. 8C). 435 
No detectable IgG antibodies against H3N2 CIV were detected in mice vaccinated with 436 
the H3N8 IIV Nobivac either using the cell extracts (Fig. 8A) or the recombinant 437 
proteins (Figs. 8B and C). The H3N2 CIV IIV induced higher IgG antibodies against 438 
H3N2 CIV in all cases, as expected (Figs. 8A-8C).  439 
The lower level of cross-reactive immunity against H3N2 CIV upon vaccination with 440 
the H3N8 LACIV was confirmed after challenge (i.n.) with H3N2 CIV 2 weeks post-441 
vaccination (Fig. 8D). Mock-vaccinated mice showed high H3N2 CIV titers that were 442 
undistinguishable from those seen in animals vaccinated with the H3N8 CIV IIV Nobivac. 443 
In contrast, mice vaccinated with the H3N2 CIV IIV showed reduced or undetectable 444 
titers at day 2 and 4 post-challenge, respectively. Although we observed similar H3N2 445 
CIV titers at day 2 post-challenge, viral titers at day 4 p.i. in mice vaccinated with the 446 
H3N8 LACIV were ~100 times lower than those obtained in the mock vaccinated group. 447 
These results suggest that H3N8 LACIV can induce limited cross-reactive immune 448 
responses and heterologous protection, most probably mediated by a T cell response, 449 
against H3N2 CIV, but that the efficacy is lower than that obtained with the H3N2 IIV. 450 
 451 
 452 
 453 
 454 
 455 
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DISCUSSION 457 
Here we report a novel LAIV prepared using plasmid-based reverse genetics 458 
techniques, which may be used for the prevention of H3N8 CIV. We have generated a 459 
recombinant H3N8 CIV containing the mutations responsible for the ts phenotype of the 460 
human A/AA/6/60 H2N2 LAIV, resulting in ts H3N8 CIV (LACIV) that was highly 461 
attenuated in vivo and ex vivo when compared to its WT counterpart. Our H3N8 LACIV 462 
was able to confer, upon a single i.n. immunization in mice, complete protection against 463 
challenge with WT H3N8 CIV. This demonstrates the feasibility of using the ts H3N8 464 
LACIV as a safe, immunogenic and protective vaccine to control H3N8 CIV in dogs. 465 
However, the H3N8 LACIV showed limited immunogenicity and protection efficacy 466 
against the heterologous H3N2 CIV, suggesting the need of a different LACIV for the 467 
treatment and control of H3N2 CIV. 468 
The ts, ca, att A/AA/6/60 H2N2 LAIV has been licensed for human use since 2003, 469 
and is used as a master donor virus (MDV) for the generation of both seasonal or 470 
potentially pandemic human LAIV by creating reassortant viruses containing the six 471 
H2N2-derived internal viral RNA (vRNA) segments (PB2, PB1, PA, NP, M, and NS) and 472 
the two glycoprotein-encoding vRNAs (HA and NA) from a virus that antigenically 473 
matches the strains predicted to circulate in the upcoming influenza season (seasonal 474 
vaccine) or potentially pandemic strains (pandemic vaccine) (50, 51). Five mutations 475 
(PB2 N265S; PB1 K391E, D581G, A661T; and NP D34G) are responsible for the ts 476 
phenotype of the A/AA/6/60 H2N2 LAIV, and those mutations also impart a strong ts 477 
phenotype and attenuation to other viral strains, such as PR8 (52, 37) and pH1N1 (38). 478 
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Intranasal immunization is a desirable delivery method for providing optimal 479 
immunity to IAV because it leads to the generation of a mucosal immune responses, 480 
creating an immune barrier at the site of potential infection (53), as well as systemic 481 
humoral responses, cellular immunity (54-56, 51, 57). Similar to infection with WT IAV, 482 
LAIV immunization also leads to recruitment of influenza-specific CD8 T cells to the 483 
lungs (49, 58, 56, 59, 60), which provides immunity against heterologous influenza 484 
challenge (49, 58). Thus, a LAIV rather than an IIV is desired for the control of IAV 485 
infections (61, 22, 27, 23). 486 
Since the emergence of H3N8 CIV in 1999 in the US and the H3N2 CIV in Asia 487 
(2005) and the US (2015), CIVs have been maintained mainly in animal shelters and 488 
kennels as those populations allow ready transmission of the virus (10, 62, 16, 17, 63). 489 
Strains of the H3 subtype of IAV infect a number of mammalian hosts, including humans, 490 
pigs, horses, dogs, cats, seals, as well as poultry (64-66, 6, 67, 63, 11). Naturally 491 
occurring H3N1 virus carrying the HA gene of an avian-like H3N2 CIV and the other 492 
seven segments of the human pH1N1 has been reported in dogs in Korea (20), 493 
suggesting that dogs could act as an intermediate host for genetic reassortment of IAV, 494 
including those that might infect humans. However, no transmission of H3N8 or H3N2 495 
CIV transmission from dogs to humans has been reported to date. It may be possible to 496 
eradicate both H3N8 and H3N2 CIVs from the dog population through infection control 497 
as well as vaccination approaches. CIV LAIVs represent a better option for efficient CIV 498 
control and probably eradication since they induce better and faster antiviral immunity.  499 
The H3N8 LACIV generated here was ts and attenuated in mice, induced protective 500 
immune responses against challenge with homologous H3N8 CIV WT, and the 501 
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responses were stronger than those obtained with a commercial H3N8 CIV IIV. Its 502 
replication and pathogenesis were also restricted in canine tracheal explants, and we 503 
are currently evaluating the safety, immunogenicity and protection efficacy of our H3N8 504 
LACIV in dogs, the real target population. 505 
To achieve protection in dogs, animals are vaccinated (i.m.) with 1 ml of the CIV 506 
H3N8 IIV (Nobivac) using a two-dose regime (68). The average weight of a male or 507 
female mouse is ~ 20 gr while the average weight of a female or male beagle dog is ~ 508 
10 kg. Thus, in principle mice should be vaccinated with 500 times less (just 2 µl) of the 509 
CIV H3N8 IIV than dogs. However, in our experiments, mice were immunized (i.m.) with 510 
100 µl of the CIV H3N8 IIV – a 50X higher dose than on a weight basis. In addition, to 511 
evaluate the amount of antigen in the CIV H3N8 IIV, we performed an hemagglutination 512 
assay (HA) using the commercial CIV H3N8 IIV or our CIV H3N8 LAIV. The assay 513 
showed that mice vaccinated with the CIV H3N8 IIV were inoculated with approximately 514 
106 viral particles/mouse of inactivated virus, 1,000 times more than the dose (103) of 515 
the H3N8 CIV LAIV. The LAIV still elicited better antibody responses and protection as 516 
compared to the CIV H3N8 IIV.  517 
Segment eight of IAV encodes the NS1 viral protein, which controls the adaptive 518 
immune responses by inhibiting the interferon (IFN)-antiviral response of the host (69). 519 
Therefore, NS1 is a virulence factor that offers an attractive target for the development 520 
of attenuated viruses as LAIVs. In fact, IAVs harboring a truncated-NS1 have been 521 
shown as promising vaccines candidates (70, 71, 28, 72-77). In a recent work, we have 522 
generated recombinant H3N8 CIVs containing truncated (NS1-126, NS1-99 or NS1-73) 523 
or deleted (ΔNS1) NS1 proteins and tested them as potential LAIVs against CIV H3N8 524 
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infections (28). The recombinant NS1 mutant H3N8 CIVs were attenuated in vivo (mice) 525 
and in vitro (dog tracheal explants), but were able to confer complete protection against 526 
challenge with WT CIV H3N8 (28). Moreover, the immunogenicity and protection 527 
efficacy of our NS1 mutant H3N8 CIVs was also better than that observed with an H3N8 528 
CIV IIV (28).  Future research should determine which one of these attenuation 529 
strategies (NS1 mutant or ts H3N8 CIVs) is more efficient for their implementation as a 530 
LAIV for the prevention and control of H3N8 CIV in dogs. 531 
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FIGURE LEGENDS 571 
Figure 1. Effect of temperature on the polymerase activity of H3N8 LACIV. A) 572 
Schematic representation of segments 1 (PB2) and 2 (PB1) of WT (black) and 573 
LACIV (gray) H3N8 CIV: Amino acid substitutions N265S (PB2) and K391E, E581G, 574 
and A661T (PB1) to generate the H3N8 LACIV are indicated. B) Minigenome activity: 575 
MDCK cells (12 well plate format, 3x105 cells/well, triplicates) were transiently co-576 
transfected with 250 ng of ambisense pDZ expression plasmids encoding the minimal 577 
requirements for viral genome replication and gene transcription (PB2, PB1, PA and 578 
NP), together with 500 ng of a vRNA-like expression plasmid encoding Gaussia 579 
luciferase (Gluc) under the control of the canine polymerase I promoter (cpPol-I Gluc), 580 
and 100 ng of a pCAGGS Cypridina luciferase (Cluc) plasmid to normalize transfection 581 
efficiencies. After transfection, cells were placed at 33ºC, 37ºC or 39ºC and viral 582 
replication and transcription was evaluated 24 h later by luminescence (Gluc). Gluc 583 
activity was normalized to that of Cluc. Data represent means and SDs. Normalized 584 
reporter expression is relative to that in the absence of pDZ NP plasmid. Data were 585 
represented as relative activity considering WT H3N8 polymerase activity at each 586 
temperature as 100%. *, P<0.05 using a Student’s t test. 587 
Figure 2. Characterization of H3N8 LACIV in vitro: MDCK cells (12 well plate format, 588 
3x105 cells/well, triplicates) were infected (MOI of 0.001) with WT (black diamonds) and 589 
LACIV (gray squares) H3N8 CIVs and incubated at 33ºC (A), 37ºC (B) and 39ºC (C). 590 
TCS were collected at 12, 24, 48, 72, and 96 h p.i. and viral titers were determined by 591 
immunofocus assay (FFU/ml). Data represent the means and SDs of the results 592 
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determined in triplicate. Dotted lines indicate the limit of detection (200 FFU/ml). *, 593 
P<0.05 using a Student’s t test. 594 
Figure 3. Attenuation of H3N8 LACIV in vivo: Female 5- to-7-week-old C57BL/6 WT 595 
mice (N=6) were infected (i.n.) with 1x105 PFU of WT or LACIV H3N8 CIVs. Three mice 596 
were sacrificed at days 2 (black) and 4 (gray) p.i. and lungs were harvested for virus 597 
titrations using an immunofocus assay (FFU/ml). Data represent the means and SDs. 598 
Dotted line indicate limit of detection (200 FFU/ml). ND, virus not detected.   599 
Figure 4. Immunogenicity of H3N8 LACIV: Female 5- to-7-week-old C57BL/6 WT 600 
mice (N=6) were vaccinated (i.n.) with 1x103 PFU of WT or LACIV H3N8 CIVs. Mice 601 
mock (PBS) vaccinated or vaccinated (i.m.) with 100 µl of an H3N8 CIV IIV  (Nobivac) 602 
were used as internal controls. A) Induction of humoral responses: At 14 days post-603 
vaccination, mice were bled and sera was evaluated for the presence of total IgG 604 
antibodies against H3N8 CIV proteins using cell extracts of MDCK-infected cells by 605 
ELISA. MDCK mock-infected cell extracts were used to evaluate the specificity of the 606 
antibody response. OD, optical density. Data represent the means +/- SDs of the results 607 
for 6 individual mice. * (Nobivac vs LACIV), ** (WT vs LACIV) or *** (WT vs Nobivac), 608 
P<0.05 using a Student’s t test. B) Hemagglutination inhibition (HAI) titers: Sera 609 
from immunized mice were evaluated by HAI using four HAU of WT H3N8 CIV and 2-610 
fold serial dilutions of the indicated sera.  ND, not detected. * (WT vs LACIV or Nobivac, 611 
and LACIV vs Nobivac), P<0.05 using a Student’s t test. 612 
Figure 5. CD8 T cell response induced by H3N8 LACIV: Female 5- to-7-week-old 613 
C57BL/6 WT mice (N=4) were vaccinated (i.n.) with 1x103 PFU of WT or LACIV H3N8 614 
CIVs. Mice mock (PBS) vaccinated or vaccinated (i.m.) with 100 µl of an H3N8 CIV IIV  615 
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(Nobivac) were used as internal controls. Ten days p.i., lungs (A) and spleen (B) were 616 
extracted and cells were prepared for flow cytometry. Live CD8 T cells specific for NP or 617 
PA tetramers were counted. Data represent the means +/- SDs of the results for 4 618 
individual mice. * (WT vs LACIV, Nobivac or PBS and LACIV vs Nobivac or PBS), 619 
P<0.05 using a Student’s t test. 620 
Figure 6. Protection efficacy of H3N8 LACIV against homologous viral challenge:  621 
Female 5- to-7-week-old C57BL/6 WT mice (N=6) were vaccinated (i.n.) with 1x103 PFU 622 
of WT or LACIV H3N8 CIVs. Mice mock (PBS) vaccinated or vaccinated (i.m.) with 100 623 
µl of an H3N8 CIV IIV  (Nobivac) were used as internal controls. At 15 days post-624 
vaccination, mice were challenged (i.n.) with 1x105 PFU of WT H3N8 CIV. To evaluate 625 
viral replication, mice were euthanized at days 2 (N=3, black) and 4 (N=3, gray) post-626 
challenge and lungs were harvested, homogenized, and used to quantify viral titers by 627 
immunofocus assay (FFU/ml). The dotted line indicates the limit of detection (200 628 
FFU/ml). ND, virus not detected. Data represent the means +/- SDs. *, P<0.05 using a 629 
Student’s t test. 630 
Figure 7. Comparison of WT and LACIV H3N8 CIV infection phenotypes in canine 631 
tracheal explants: A) Histological features of dog tracheal explants infected with 200 632 
PFU of H3N8 WT CIV, H3N8 LACIV or mock-infected with infection media. Lesions are 633 
shown in sections stained with haematoxylin and eosin (H&E). B) CIV H3N8 infected 634 
cells were detected by immunostaining for the viral NP and positive cells are stained in 635 
brown. For both (A) and (B) panels, pictures are representatives of three independent 636 
experiments and black horizontal bars represent 20μm. C) Graphical representation of 637 
the bead clearance average time of CIV- or mock-infected dog tracheal explants for 638 
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three independent experiments. Data represent the means +/- SDs. Ns, p>0.05 (D1: 639 
LACIV vs Mock); *, p<0.05 (D1: WT vs Mock); **, p<0.01 (D3: LACIV vs Mock); ***, 640 
p<0.001 (D3: WT vs Mock); ****, p<0.0001 (D5: LACIV and WT vs Mock).  D) Average 641 
viral replication of H3N8 LACIV and H3N8 WT CIV in canine tracheal explants from 642 
three independent experiments. Data represent the means +/- SDs. Dotted line indicate 643 
limit of detection (20 FFU/ml).  644 
Figure.8: Immunogenicity and protection efficacy of H3N8 LACIV against 645 
heterologous H3N2 CIV challenge: Female 5- to-7-week-old C57BL/6 WT mice were 646 
vaccinated (i.n.) with 1x103 PFU of WT and LACIV H3N8 CIVs. Mice mock (PBS) 647 
vaccinated or vaccinated (i.m.) with 100µl of the H3N8 (Nobivac) and an H3N2 CIV IIV 648 
(Zoetis) were used as internal controls. A to C) Antibody cross-reactivity against the 649 
heterologous CIV H3N2: At 14 days post-vaccination, mice were bled and sera was 650 
evaluated by ELISA for total IgG antibodies against H3N2 CIV proteins using cell 651 
extracts of MDCK-infected cells (A). Mock-infected MDCK cell extracts were used to 652 
evaluate the specificity of the antibody response. OD, optical density. Data represent 653 
the means +/- SDs of the results for 6 individual mice. * (Nobivac vs LACIV), ** (WT vs 654 
LACIV) or *** (WT vs Nobivac), P<0.05 using a Student’s t test. Specific antibody 655 
response against recombinant HA (B) and NA (C) proteins from H3N2 CIV were 656 
evaluated by ELISA. Data represent the means +/- SDs of the results for pooled sera 657 
samples. * (WT vs LACIV), P<0.05 using a Student’s t test.  D) Protection efficacy of 658 
H3N8 LACIV against heterologous H3N2 CIV challenge: At 15 days post-vaccination, 659 
mice were challenged (i.n.) with 1x105 PFU of WT H3N2 CIV. To evaluate WT H3N2 660 
CIV replication, mice were sacrificed at days 2 (N=3, black) and 4 (N=3, gray) post-661 
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challenge and lungs were harvested, homogenized, and used to evaluate the presence 662 
of virus by immunofocus assay (FFU/ml). The dotted line indicates the limit of detection 663 
(200 FFU/ml). ND, virus not detected. Data represent the means +/- SDs. *, P<0.05 664 
using a Student’s t test. 665 
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